Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders

• Published in: Pharmacological research 2018-06, Vol.132, p.1-6
• Main Authors: Israelyan, Narek, Margolis, Kara Gross
• Format: Article
• Language: English
• Subjects: Animals; Autism spectrum disorder; Autism Spectrum Disorder - metabolism; Brain - metabolism; Enteric nervous system; Gastrointestinal Microbiome; Gut-brain-microbiome axis; Humans; Serotonin; Serotonin - metabolism; Serotonin 4 receptor; Serotonin Plasma Membrane Transport Proteins - metabolism; Serotonin reuptake transporter
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2018.03.020

Autism-spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and repetitive patterns of behavior. ASD is, however, often associated with medical comorbidities and gastrointestinal (GI) dysfunction is among the most common. Studies have demonstrated a correlation between GI dysfunction and the degree of social impairment in ASD. The etiology of GI abnormalities in ASD is unclear, though the association between GI dysfunction and ASD-associated behaviors suggest that overlapping developmental defects in the brain and the intestine and/or a defect in communication between the enteric and central nervous systems (ENS and CNS, respectively), known as the gut-brain axis, could be responsible for the observed phenotypes. Brain-gut abnormalities have been increasingly implicated in several disease processes, including ASD. As a critical modulator of ENS and CNS development and function, serotonin may be a nexus for the gut-brain axis in ASD. This paper reviews the role of serotonin in ASD from the perspective of the ENS. A murine model that has been demonstrated to possess brain, behavioral and GI abnormalities mimicking those seen in ASD harbors the most common serotonin transporter (SERT) based mutation (SERT Ala56) found in children with ASD. Discussion of the gut-brain manifestations in the SERT Ala56 mice, and their correction with developmental administration of a 5-HT4 agonist, are also addressed in conjunction with other future directions for diagnosis and treatment.